← Back to Search

P2Y12 receptor inhibitor

Ticagrelor 90mg for Acute Coronary Syndrome (TC4 Trial)

Phase 4
Waitlist Available
Led By James Brophy, MD, PhD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

Summary

This trial is testing two combinations of blood-thinning medications to find out which is safer and more effective for patients with heart problems. The medications help prevent blood cells from forming clots, reducing the risk of heart attacks.

Eligible Conditions
  • Acute Coronary Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
The (The hazard ratio for the number of participants that develop the outcome, a composite of cardiovascular-related mortality, myocardial infarction (MI), or stroke) stratified by sex
The (The hazard ratio for the number of participants that develop the outcome, a composite of cardiovascular-related mortality, myocardial infarction (MI), or stroke) stratified by sex.
The hazard ratio for the number of participants that develop the outcome, a composite of cardiovascular-related mortality, myocardial infarction (MI), or stroke.
+6 more

Side effects data

From 2021 Phase 3 trial • 76 Patients • NCT03649711
48%
Bruise
20%
Dyspnea
8%
Fatigue
4%
Hospitalization
100%
80%
60%
40%
20%
0%
Study treatment Arm
Experimental: CKD-Ticagrelor
Arm: Active Comparator: CKD-Clopidogrel
Arm: Active Comparator: Control-ticagrelor

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ticagrelor 90mgExperimental Treatment2 Interventions
Ticagrelor: 180 mg loading dose followed by 90 mg BID. Aspirin: 325 loading dose followed by 81 mg daily.
Group II: Clopidogrel 75mgActive Control2 Interventions
Clopidogrel: 300 mg loading dose followed by 75 mg daily. Aspirin: 325 loading dose followed by 81 mg daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ticagrelor
FDA approved
Acetylsalicylic acid
FDA approved

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
452 Previous Clinical Trials
160,854 Total Patients Enrolled
1 Trials studying Acute Coronary Syndrome
65 Patients Enrolled for Acute Coronary Syndrome
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,354 Previous Clinical Trials
26,459,481 Total Patients Enrolled
9 Trials studying Acute Coronary Syndrome
8,921 Patients Enrolled for Acute Coronary Syndrome
James Brophy, MD, PhDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre
~150 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top